---
title: "JinJi: The company's H acid product line will begin trial production soon"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/246227918.md"
description: "On June 26, JinJi stated on the interactive platform that the company's production capacity for the H acid product line, which is 8,000 tons/year, will soon begin trial production. After passing the trial production acceptance, it will officially go into production. Once the product capacity is formed, most of it will be used for the production of reactive dyes for internal use, with the excess portion sold externally, having a minimal impact on operating income"
datetime: "2025-06-26T10:06:23.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/246227918.md)
  - [en](https://longbridge.com/en/news/246227918.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/246227918.md)
generator: "portal-rs"
---

# JinJi: The company's H acid product line will begin trial production soon

On June 26th, JinJi stated on the interactive platform that the company's production capacity for the H acid product line, which is 8,000 tons per year, will soon begin trial production. After passing the trial production acceptance, it will officially go into production. Once the product capacity is established, most of it will be used for self-production of reactive dyes, with the excess portion sold externally, having a minimal impact on operating income

### Related Stocks

- [300798.CN](https://longbridge.com/en/quote/300798.CN.md)

## Related News & Research

- [EXPLAINER-Haiti's conflict in numbers as gangs inflict another night of terror](https://longbridge.com/en/news/297076683.md)
- [Nearly 25K pounds of frozen buffalo chicken recalled over inspection lapse](https://longbridge.com/en/news/297124023.md)
- [MSC halts Russian Black Sea service after drone attack, Bloomberg News reports](https://longbridge.com/en/news/297066548.md)
- [Heidelberg Pharma, Huadong Medicine expand ADC collaboration to develop new drug candidates](https://longbridge.com/en/news/297291658.md)
- [Heidelberg Pharma says China NMPA clears HDP-101 combo trial in multiple myeloma](https://longbridge.com/en/news/297070749.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**